Molecure

The #Molecure team was represented by Piotr Iwanowski (CMO), Theodoros Charitos (Medical Director) and Geolyce Mpofu (Director, Patient Recruitment and Site Engagement) at the 5th National Conference on #Sarcoidosis Diagnosis and Treatment, held in Rome, Italy, on April 17-18 🔬

Hello from Lisbon! ☀️ Our team: Marcin Szumowski (CEO), Zbigniew Zaslona (CSO) and Maurycy Zieliński (Business Development Director), is currently attending #BIOEurope Spring 2026 in Portugal 🇵🇹 Great conversations and meaningful connections at #BIOEuropeSpring!

This Friday, our CEO Marcin Szumowski will join a panel discussion at Invest Cuffs 2026 💡 🕑 14:20 | Panel Discussion - moderated by Agata Dzięciołowska, ccgroup Panel title: “Biotech 2026: Which Global Trends Will Polish Companies Benefit From?” We’re excited to join! 🌍

#Molecure's financial report for 2025 is now available on our website 📈 Click here to view the full report (section "Raporty giełdowe") ➡️ molecure.com/pl/informacje-…

#Molecure invites you to an investor meeting dedicated to discussing the company's operational and financial situation for FY 2025 📊 🗓️ Join us on March 11th at 09:00 AM (CET) ➡️ ccgroup.clickmeeting.com/molecure-s-a-w…

We are pleased to share that our CEO Marcin Szumowski will join a panel discussion and fireside chat at the Life Science Investor Day by Strefa Inwestorów @strefainw on March 11. 🔗 Learn more about the event: strefainwestorow.pl/wydarzenia/260…

We are pleased to announce the publication dates for Molecure's 2026 reports 📣 ➡️ Annual Report for 2025 - March 31, 2026 ➡️ Q1 2026 Report - April 30, 2026 ➡️ Report for the First Half of 2026 - September 30, 2026 ➡️ Q3 2026 Report - October 30, 2026 Stay tuned for updates 🔬

New interview with #Molecure’s CEO Marcin Szumowski now available! 🎙️ 👉 Read the full interview here: strefainwestorow.pl/biotechnologia…

Hello from Vienna! 🇦🇹 Our team: Marcin Szumowski (CEO), Zbigniew Zasłona (CSO) and Maurycy Zieliński (Business Development Director), is attending #BIOEurope 2025, connecting with biotech and pharma leaders from around the world 🧬

We’re excited to announce that #Molecure will be attending #BIOEurope 2025 in Vienna, Austria, from November 3-5! 🇦🇹 Representing us on-site will be: Marcin Szumowski - CEO, Zbigniew Zasłona - CSO and Maurycy Zieliński - Business Development Director 🤝See you in Vienna! 👋

Recently, our team had the pleasure of attending the 5th International Conference WE! Are Clinical Research, organized by Kozminski University and Medical University of Warsaw (WUM)✨ It’s inspiring to be part of a community driving responsible and innovative clinical research 🔬

📣 Join us TODAY for an investor meeting dedicated to discussing the company's operational and financial situation for 1H 2025 📊 🗓️ October 2nd at 1:00 PM (CEST) PL: livingmedia.com.pl/live/molecure/… ENG: livingmedia.com.pl/live/molecure/…

The H1 2025 report is now available on our website 📈 Click here to view the full report (section "Raporty giełdowe") ➡️ molecure.com/pl/informacje-…

📢Our latest publication, developed in collaboration with the Medical University of Warsaw (WUM), "Therapeutic inhibition of USP7 promotes antitumor immune responses", is now out! 🧬 📄 Read the full article in Journal for ImmunoTherapy of Cancer: 👉 jitc.bmj.com/content/13/9/e…

#Molecure was at the Polish Chemical Society (#PTChem) conference in Wrocław 🔬 Our Senior Scientist, Wojciech Czestkowski, gave a presentation on a first-in-class small molecule modulator of YKL-40 as a potential treatment for inflammatory, fibrotic & neoplastic diseases 💊

Our Head of Medicinal Chemistry, Roman Błaszczyk, presented at the XII Medicinal Chemistry Symposium in Lublin on “Boronic Acids as Arginase Inhibitors: Discovery and Development of the Polish Experimental Immuno-Oncology Drug #OATD02”🔬

We are pleased to announce that Molecure has been granted its first patent (US12404279 (B2)) covering a novel series of #USP7 inhibitors 💡 This achievement highlights the originality of our science and our mission to deliver first-in-class small molecule therapies for patients🔬

We are proud to share that our Medicinal Chemist - Principal Scientist, Jacek Chrzanowski, is currently attending EFMC-ASMC 2025 in Porto, where he presented a poster on USP7 inhibitors research.

#Molecure has obtained all required approvals to start the #KITE clinical trial with #OATD01 in the Netherlands 🇳🇱 We are preparing to initiate patient recruitment in two Dutch centers, expecting that expanding the trial to the Netherlands will improve recruitment efficiency ✅

This week, #Molecure is attending the 10th European Conference on Boron Chemistry in Łódź, where our Senior Scientist, Julita Nowicka, delivered an oral presentation titled: “Novel Boron-based Arginase Inhibitor OATD-02: from Discovery to Clinical Trials in Cancer Immunotherapy”.